Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Pei-Yi Lin has more than 10 years of experience in the field of cell and gene therapy. She obtained her Ph.D. in Immunology in 2011 from University of Texas Health Science Center. Her Ph.D. research focused on understanding how immune-checkpoint inhibitors, such as PD-1 and PD-L1, change the immune response in patients with cancer, autoimmunity, infections, and age-related debilities. From 2011 to 2014 she worked in an academic research lab, developed adoptive cell transfer and vaccine based strategies for protecting and repairing the central nervous system in autoimmune and neurodegenerative diseases. In 2014, Pei-Yi took a position as a research and process development scientist at Bellicum Pharmaceuticals, Inc. in Houston, TX. She spent two and half years at Bellicum in a number of roles doing not only pre-clinical translational studies but also development of GMP manufacturing processes for CAR-T and TCR cell therapies in early phase clinical trials. Her current position at Thermo Fisher is R&D Lead of Cell Culture Media Development in Cell Therapy BioProduction, where she leads and manages the Cell Culture media R&D organization charged with the development and commercialization of cell culture media and services for regenerative medicine-related industries such as CAR-T cell therapy. Since joining Thermo Fisher in August 2016, she has participated in the development, process design, and optimization of the T cell isolation & expansion platforms including CTS™ Dynabeads™ CD3/CD28, DynaMag™, Finesse SmartRocker and SmartVessel, and catalog/custom T cell expansion media & supplements.